Xiaoqian Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoqian Wu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Antonia E. Gallman
Department of Laboratory Medicine, Yale University School of Medicine , New Haven, CT
1 shared publication - Arthur Richard Kitching
Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria 3168, Australia
1 shared publication - Carola G. Vinuesa
Francis Crick Institute, London, UK
1 shared publication - Chengmei Xie
Centre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 1
1 shared publication - Finn D. Wolfreys
University of California
1 shared publication - Haiyan Xue
Department of Pediatrics, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China 5
1 shared publication
Latest Publications
- Open Access
- 10 December 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (1)
P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance
B cell self-tolerance is maintained through multiple checkpoints, including restraints on intracellular signaling and cell trafficking. P2RY8 is a receptor with established roles in germinal center (GC) B cell migration inhibition and growth regulation. Somatic P2RY8 variants are common in GC-derived B cell lymphomas. Here, we identify germline novel or rare P2RY8 missense variants in lupus kindreds or the related antiphospholipid syndrome, including a “de novo” variant in a child with severe nephritis. All variants decreased protein expression, F-actin abundance, and GPCR-RhoA signaling, and those with stronger effects increased AKT and ERK activity and cell migration. Remarkably, P2RY8 was reduced in B cell subsets from some SLE patients lacking P2RY8 gene variants. Low P2RY8 correlated with lupus nephritis and increased age-associated B cells and plasma cells. By contrast, P2RY8 overexpression in cells and mice restrained plasma cell development and reinforced negative selection of DNA-reactive developing B cells. These findings uncover a role of P2RY8 in immunological tolerance and lupus pathogenesis.
- 10 December 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (1)
Open AccessP2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance
B cell self-tolerance is maintained through multiple checkpoints, including restraints on intracellular signaling and cell trafficking. P2RY8 is a receptor with established roles in germinal center (GC) B cell migration inhibition and growth regulation. Somatic P2RY8 variants are common in GC-derived B cell lymphomas. Here, we identify germline novel or rare P2RY8 missense variants in lupus kindreds or the related antiphospholipid syndrome, including a “de novo” variant in a child with severe nephritis. All variants decreased protein expression, F-actin abundance, and GPCR-RhoA signaling, and those with stronger effects increased AKT and ERK activity and cell migration. Remarkably, P2RY8 was reduced in B cell subsets from some SLE patients lacking P2RY8 gene variants. Low P2RY8 correlated with lupus nephritis and increased age-associated B cells and plasma cells. By contrast, P2RY8 overexpression in cells and mice restrained plasma cell development and reinforced negative selection of DNA-reactive developing B cells. These findings uncover a role of P2RY8 in immunological tolerance and lupus pathogenesis.